Omniscan (Gadodiamide)

Gadodiamide, the active ingredient in Omniscan, is a gadolinium‑based contrast agent presented as an injectable solution for intravenous use. It enhances magnetic resonance imaging of the brain, spine, cardiovascular system and other body regions in both adult and pediatric patients.

GNH USA supplies Omniscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, imaging centres and clinics worldwide. The product complies with EU regulatory standards and is distributed under strict quality assurance protocols. It is intended for use by qualified radiology professionals in diagnostic imaging procedures.

Omniscan (gadodiamide) is used as a gadolinium‑based contrast medium to improve magnetic resonance imaging across several clinical areas.

Central nervous system MRI: improves detection and delineation of lesions, tumors and vascular abnormalities. Magnetic resonance angiography (MRA): enhances visualization of arterial and venous structures. Abdominal and pelvic MRI: provides superior tissue contrast for assessment of tumors and inflammatory conditions. Cardiac MRI: assists in evaluating myocardial perfusion and scar tissue.

Gadodiamide may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Headache: transient discomfort after injection. - Injection site pain or warmth: brief sensation at the infusion site. - Dizziness: temporary light‑headedness.

Serious or Rare Side Effects: - Nephrogenic systemic fibrosis (NSF): a rare fibrotic disorder in patients with severe renal impairment. - Severe allergic reactions: including anaphylaxis, bronchospasm and urticaria. - Gadolinium retention: long‑term deposition in brain or bone tissue, of uncertain clinical significance. - Renal failure exacerbation: worsening of pre‑existing kidney dysfunction.

Before administering Omniscan, clinicians should observe several safety measures.

Renal function assessment: evaluate glomerular filtration rate before administration. History of contrast reactions: screen patients for prior hypersensitivity to gadolinium agents. Pregnancy: use only when essential, after risk‑benefit analysis. Breastfeeding: consider potential exposure and discuss with healthcare provider. Concurrent nephrotoxic drugs: monitor renal status closely. Store at ambient temperature: keep in original container, protect from light and moisture.

Gadodiamide can interact with other medicines or agents that affect renal function or cumulative gadolinium exposure.

Major Interactions (Avoid): - Severe renal impairment drugs (e.g., high‑dose NSAIDs): increase risk of NSF. - Concurrent use of other gadolinium agents: may lead to cumulative gadolinium load. - Iodinated contrast media: combined renal stress may worsen kidney function.

Moderate Interactions (Monitor Closely): - Diuretics: monitor fluid and electrolyte balance during imaging. - Metformin: assess renal function and consider temporary discontinuation per guidelines.